Bristol-Myers Squibb, Amgen and Abbott Labs all recently raised their dividends and should prosper amid the aging population.
One of my investment themes, as I look for structural changes tied to the evolving economic, demographic, technological and psychographic landscapes, is the Aging of the Population. It’s no secret that several countries are experiencing a demographic shift in their populations that skews older. Here in the U.S., the first baby boomers started turning 70 in 2016, but in the coming years, the percentage of the U.S. population that is 65 years or older will explode.
By 2030, all baby boomers will be older than age 65. This will expand the size of the older population so that one in every five residents will be retirement age. At the same time, we are living longer, with the most recent data published by the Census Bureau showing average U.S. life expectancy rose to 78.6 years in 2017, up from 68 years in 1950. According to data published by Care Patrol, which focuses on safer senior living, by 2020 roughly 15 million of the elderly population in the U.S. will have some form of disability and by 2030, “more than 6 of every 10 boomers will manage more than one chronic condition.”
More people living longer is a development that will give rise to greater and in some ways different demands…